Table 4. Does cisplatin-based chemotherapy affect SC?

	Cisplatin-based (N=181)	Non-cisplatin (N=184)	Pa
Drugs against treatment side effects	120 (66%)	113 (61%)	0.33
A01 Stomatologicals	0	0
A02 Antacids	39 (22%)	39 (21%)
A03 Antispasmodics	28 (15%)	31 (17%)
A04 Antiemetics	75 (41%)	49 (27%)
A06 Laxatives	14 (8%)	18 (10%)
A07 Antidiarrhoeals	9 (5%)	6 (3%)
B02 Antihaemorrhagics	2 (1%)	10 (5%)
B03 Antianaemics	19 (10%)	8 (4%)
J01 Antibacterials for systemic use	15 (8%)	18 (10%)
J02 Antimycotics for systemic use	4 (2%)	4 (2%)
L03AA Colony-stimulating factors	23 (13%)	19 (10%)
Drugs against tumour symptoms	104 (57%)	98 (53%)	0.42
A14 Anabolic agents for systemic use	2 (1%)	2 (1%)
A15 Appetite stimulants	0	0
B01 Antithrombotic agents	7 (4%)	3 (2%)
H01AA ACTH	2 (1%)	3 (2%)
H02 Corticosteroids for systemic use	70 (39%)	61 (33%)
L02AB Progestogens	3 (2%)	0
M01A Nonsteroidal anti-inflammatory drugs	38 (21%)	26 (14%)
M05B Drugs affecting mineralisation	8 (4%)	5 (3%)
N02A Opioids	19 (10%)	10 (5%)
N02B Other analgesics and antipyretics	18 (10%)	21 (11%)
N03 Antiepileptics	0	2 (1%)
R03 Antiasthmatics	9 (5%)	15 (8%)
R05C Expettorants	4 (2%)	3 (2%)
R05D Cough suppressants	9 (5%)	11 (6%)
Drugs against concomitant diseases	20 (11%)	12 (7%)	0.13
A10 Antidiabetics	4 (2%)	1 (1%)
C Cardiovascular system	16 (9%)	5 (3%)
G04 Drugs for prostatic hypertrophy	0	1 (1%)
H03 Drugs for thyroid	0	1 (1%)
N05 Psycholeptics	2 (1%)	2 (1%)
N06 Psychoanaleptics	1 (2%)	2 (1%)
N07C Antivertigo preparations	0	0

Adult Italian patients randomized in the GEMVIN3 study. The table shows the number (percentage) of patients assuming at least one drug of each category during the first 63 days of treatment

^aχ² test.